▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications
Fibrosis is an independent predictor of liver-related mortality but rarely if ever occurs without NASH as NASH is the progressive form of the disease and drives fibrosis progression. This means the question arises on whether anti-fibrotic drugs are better than anti-NASH drugs and vice versa which Dr. Vlad Ratziu explores in this video.
View More ⏩Fibrosis vs. steatohepatitis in NASH: key prognostic and regulatory implications
Burden of Liver-Related Comorbidities in Cardiovascular Disease
In this video Prof. Sven Francque explores that NAFLD is prevalent in patients with cardiovascular disease, but this does not prove bidirectional causality. Vascular mechanisms contribute to NASH pathogenesis and drugs used in CVD management show some benefit on NAFLD.
View More ⏩Burden of Liver-Related Comorbidities in Cardiovascular Disease
How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and management into the care of diabetic patients in order to provide a holistic approach for the patient in order for improved patient outcomes.
View More ⏩How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient
HCC Pathogenesis in NASH and the Impact of Fibrosis
Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This video is adapted from a lecture Dr. Scott Friedman gave at the Paris NASH meeting and illustrates the highlights of that topic in this video.
View More ⏩HCC Pathogenesis in NASH and the Impact of Fibrosis
Natural history & clinical outcomes in adults with NAFLD
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic fatty liver disease (NAFLD) with lessons from cohort studies and placebo arms of trials. The take home points are that the natural history of NAFLD is variable
View More ⏩Natural history & clinical outcomes in adults with NAFLD
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in the progression of chronic liver diseases. The key points addressed in this video are that co-existent fatty liver and related metabolic factors, including obesity and diabetes mellitus, exacerbate liver injury in patients with another chronic liver disease(s).
View More ⏩The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
NASH Treatment: Review of Current and Future Therapies for Non-Alcoholic Steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a focus on the pathogenesis of NASH and the different pathways on how underlying steatohepatitis is developed, he presents his expert perspective on how patient outcomes can be improved.
View More ⏩NASH Treatment: Review of Current and Future Therapies for Non-Alcoholic Steatohepatitis
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of non-alcoholic fatty liver disease, NAFLD.
View More ⏩Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 2022. He focuses on the benefits of lifestyle recommendations, including nutrition and exercise. He shows that weight loss is associated with NASH resolution and fibrosis regression over time following bariatric surgery in patients with severe obesity and NASH.
View More ⏩NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)
This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered by international experts with a multidisciplinary approach: Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom, and Prof. Sven Francque, along with chair, Prof. Stefan Anker. They review the epidemiology of NAFLD / NASH, its increasing prevalence rates, and discuss current best practices to improve patient outcomes.
View More ⏩Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)
GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3)
In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.
View More ⏩GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3)
Getting to the heart of nafld/nash – the cvd perspective (part 2)
Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular (CVD) disease in this video along with joint pathophysiological pathways and its shared drivers. He further looks into NAFLD and its relationships and effects with atherosclerotic CVD and heart failure. For clinicians, he provides an analyses of the management and diagnosis options for advanced NAFLD.
View More ⏩Getting to the heart of nafld/nash – the cvd perspective (part 2)
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES